Skip to main content
SpringerLink
Log in

Stimulation of growth hormone secretion with human growth hormone releasing factors (GRF1–44, GRF1–40, GRF1–29) in normal subjects

  • Wissenschaftliche Kurzmitteilung
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

Peptides of different chain lengths (GRF1–44, GRF1–40, GRF1–29) were given as a 50 µg i.v. bolus to five normal volunteers. Blood was collected before and until 120 min after GRF injection. No serious side effects were recorded. All GRF peptides led to a clearcut and significant increase of GH levels compared to placebo controls with the maximum occurring 15–30 min after GRF injection. There was no significant difference in the maximal GH increase after the different GRF peptides. When GRF1–44 was administered to five normal subjects over 2 days in 6- and 18-h intervals, respectively, significant increase of GH levels were recorded after each injection compared to placebo controls. Again, there was no significant difference between the maximal GH rises during the different tests. These findings show that the short GRF1–29 peptide may be used for diagnosis and therapy. In addition, in contrast to continuous infusion and administration of GRF in short intervals, GRF application in 6-h intervals leads to adequate GH responses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

(h) GH:

(human) growth hormone

hpGRF:

human pancreatic growth hormone releasing factor

References

  1. Borges ILC, Blizzard RM, Evans WS, Furlanetto R, Rogol AD, Kaiser DL, Rivier J, Vale W, Thorner MO (1984) Stimulation of growth hormone (GH) and somatomedin C in idiopathic GH-deficient subjects by intermittent pulsatile administration of synthetic human pancreatic tumour GH-releasing factor. J Clin Endocrinol Metab 59:1–6

    PubMed  Google Scholar 

  2. Grossman A, Lytras N, Savage MO, Wass JAH, Coy DH, Rees LH, Jones AE, Besser GM (1984) Growth hormone releasing factor: comparison of two analogues and demonstration of hypothalamic defect in growth hormone release after radiotherapy. Br Med J 288:1785–1787

    Google Scholar 

  3. Guillemin R, Ling N, Esch F, Böhlen P, Brazeau P, Wehrenberg W, Baird A, Bloch B, Mougin C, Zeytin F (1984) Growth hormone-releasing factor. An update. 7th International Congress of Endocrinology, July 1–7, Quebec City. Excerpta Medica, Amsterdam, International Congress Series 652, p 179

  4. Guillemin R, Zeytin F, Ling N, Böhlen P, Esch F, Brazeau P, Bloch B, Wehrenberg WB (1984) Growth hormone-releasing factor: Chemistry and physiology. Proc Soc Exp Biol Med 175:407–413

    PubMed  Google Scholar 

  5. Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB (1982) Growth hormone releasing factor from a human pancreatic tumor that caused acromegaly. Science 218:585–587

    PubMed  Google Scholar 

  6. Lance VA, Murphy WA, Sueiras-Diaz J, Coy DH (1984) Superactive analogues of growth hormone-releasing factor (1–29) — amide. Biochem Biophys Res Commun 119:265–272

    PubMed  Google Scholar 

  7. Losa M, Stalla GK, Müller OA, von Werder K (1983) Human pancreatic growth hormone-releasing factor (hpGRF): dose-response of GRF-and GH-levels. Klin Wochenschr 61:1249–1253

    PubMed  Google Scholar 

  8. Losa M, Bock L, Schopohl J, Stalla GK, Müller OA, von Werder K (1984) Growth hormone releasing factor infusion does not sustain elevated GH-levels in normal subjects. Acta Endocrinol (Kbh), in press

  9. Rivier J, Spiess J, Thorner MO, Vale W (1982) Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature 300:276–278

    PubMed  Google Scholar 

  10. Rosenthal SM, Schriock EA, Kaplan SL, Guillemin R, Grumbach MM (1983) Synthetic human pancreas growth hormone-releasing factor (hpGRF1–44 NH 2) stimulates growth hormone secretion in normal men. J Clin Endocrinol Metab 57:677–679

    PubMed  Google Scholar 

  11. Thorner MO, Spiess J, Vance ML, Rogol AD, Kaiser DL, Webster JD, Rivier J, Borges JL, Bloom SR, Cronin MJ, Evans WS, Mac Leod RM, Vale W (1983) Human pancreatic growth hormone releasing factor selectively stimulates growth hormone secretion in man. Lancet I:24–28

    Google Scholar 

  12. Werder K von (1975) Wachstumshormone und Prolaktinsekretion des Menschen. U-S Manuskript. Urban und Schwarzenberg, München Berlin Wien

    Google Scholar 

  13. Werder K von, Müller OA, Hartl R, Losa M, Stalla GK (1984) Growth hormone-releasing factor (hpGRF)-stimulation test in normal controls and acromegalic patients. J Endocrinol Invest 7:185–191

    PubMed  Google Scholar 

  14. Wood SM, Ch'ng JCL, Adams EF, Webster JD, Joplin GF, Mashiter K, Bloom SR (1983) Abnormalities of growth hormone release in response to human pancreatic growth hormone releasing factor [GRF (1–44)] in acromegaly and hypopituitarism. Br Med J 286:1687–1691

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik Innenstadt, Universität München, Germany

    M. Losa, J. Schopohl, O. A. Müller & K. von Werder

Authors
  1. M. Losa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Schopohl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O. A. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. von Werder
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported by the Deutsche Forschungsgemeinschaft (We 439/4-1) and the Fraunhofergesellschaft

Rights and permissions

Reprints and permissions

About this article

Cite this article

Losa, M., Schopohl, J., Müller, O.A. et al. Stimulation of growth hormone secretion with human growth hormone releasing factors (GRF1–44, GRF1–40, GRF1–29) in normal subjects. Klin Wochenschr 62, 1140–1143 (1984). https://doi.org/10.1007/BF01782473

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01782473

Key words

Search

Navigation